The Marksans Pharma Ltd prices are delayed, login to your account for live prices
LOGIN
Marksans Pharma Ltd Share Price
Pharmaceuticals - Indian - Formulations
As on 22 January 2025 at 18:33 IST
About Marksans Pharma Ltd
Marksans Pharma Limited is a prominent Indian pharmaceutical company. It is primarily engaged in the manufacturing and marketing of pharmaceutical formulations. The company operates in the pharmaceutical sector, specializing in healthcare and life sciences. It focuses on developing solutions that enhance patient care and overall health outcomes. Its headquarters is in Oshiwara, Andheri (W), Mumbai, Maharashtra. The company was founded in 2000 and offers a wide range of pharmaceutical formulations. These include analgesics, antibiotics, antidiabetics, cardiovascular drugs, and gastrointestinal medications. The company also produces over-the-counter (OTC) products and nutraceuticals. Read More...
Over 1 Month
-11.78%
Over 6 Months
38.06%
Over 1 Year
72.59%
Over 3 Years
339.61%
Marksans Pharma Ltd Summary
Close
₹
252.45
Open
₹
259.55
High
₹
259.55
Low
₹
246.05
Volume
7,49,012
Net Turnover (in ₹)
₹
22,00,42,834.50
52Wk High
₹
358.70
52Wk Low
₹
130
52Wk High / Low
130
358.70
Marksans Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in ₹Cr)
₹
11,743.74
EPS (TTM)
3.39
Book Value (BV)
28.49
Div. Yield
0.23
%
P/E (TTM)
76.46
Price/Book Value
9.10
Delivery %
32.99
%
Face Value
1
Key Ratios
PE Ratio
51.37
PB Ratio
5.62
EV to Sales
7.69
PEG Ratio
1.71
ROA
10.83
ROE
11.46
Debt-Equity
0.01
Net Profit Margin
15.68
Operating Profit Margin
23.67
Marksans Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 2,227.83 | 1,911.45 | 1,532.69 | 1,382.88 | 1,134.54 |
| Total Expenses | 1,804.30 | 1,573.80 | 1,285.18 | 1,080.71 | 977.36 |
| Profit Before Tax | 423.53 | 337.65 | 247.51 | 302.16 | 157.17 |
| Profit After Tax | 314.89 | 265.32 | 186.81 | 238.54 | 120.75 |
| Operating Profit after Depreciation | 434.73 | 346.78 | 255.96 | 310.15 | 165.92 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 779.97 | 488.93 | 430.19 | 315.44 | 302.72 |
| Total Non Current Assets | 818.46 | 515.09 | 438.90 | 326 | 309.08 |
| Total Current Assets | 1,862.49 | 1,675.30 | 1,201.20 | 902.82 | 593.59 |
| TOTAL ASSETS | 2,680.95 | 2,190.39 | 1,640.10 | 1,228.82 | 902.67 |
| Total Shareholder's Fund | 2,065.05 | 1,745.16 | 1,202.27 | 886.50 | 636.01 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | 230.41 | 237.41 | 99.26 | 178.59 | 233.33 |
| Net Cash used in Investing Activities | -140.84 | -259.21 | -84.39 | -44.85 | -59.58 |
| Net Cash used in Financing Activities | -68.73 | 197.83 | 79.51 | -15.29 | -113.55 |
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 915.35 | 715.69 | 700.54 | 630.70 | 433.59 |
| Total Expenses | 743.45 | 583.65 | 566.03 | 506.37 | 380.86 |
| Profit Before Tax | 171.89 | 132.03 | 134.51 | 124.33 | 52.73 |
| Profit After Tax | 133.76 | 102.87 | 103.99 | 98.38 | 37.90 |
| Operating Profit after Depreciation | 172.88 | 135.65 | 138.30 | 129.68 | 60.02 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 271.57 | 143.94 | 135.51 | 129.09 | 115.18 |
| Total Non Current Assets | 568.33 | 431.10 | 375.75 | 369.32 | 355.73 |
| Total Current Assets | 947.70 | 913.76 | 589.86 | 371.38 | 244.05 |
| TOTAL ASSETS | 1,516.04 | 1,344.86 | 965.61 | 740.69 | 599.78 |
| Total Shareholder's Fund | 1,222.70 | 1,111.32 | 784.67 | 599.72 | 505.63 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | 34.05 | 51.73 | 55.97 | 106.92 | 107.58 |
| Net Cash used in Investing Activities | -114.22 | -194.62 | -128.06 | 8.87 | -24.15 |
| Net Cash used in Financing Activities | -26.22 | 210.02 | 70.86 | -13.53 | -81.87 |
| Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
|---|---|---|---|---|---|
| Total Revenue | 641.92 | 590.62 | 560.01 | 586.13 | 531.24 |
| Total Expenses | 506.24 | 462.19 | 450.37 | 453.11 | 417.29 |
| Profit Before Tax | 124.60 | 120.02 | 100.27 | 112.66 | 113.77 |
| Profit After Tax | 97.76 | 89.07 | 77.64 | 82.97 | 83.85 |
| Operating Profit after Depreciation | 146.74 | 143.38 | 126.17 | 137.82 | 132.95 |
| Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
|---|---|---|---|---|---|
| Total Revenue | 308.63 | 254.53 | 225.20 | 241.36 | 204.67 |
| Total Expenses | 256.35 | 213.26 | 191.29 | 199.39 | 167.37 |
| Profit Before Tax | 76.34 | 42.30 | 38.40 | 34.60 | 44.50 |
| Profit After Tax | 63.20 | 32.02 | 32.99 | 25.29 | 31.29 |
| Operating Profit after Depreciation | 83.64 | 49.42 | 46.10 | 43.30 | 53.23 |
Marksans Pharma Ltd Technicals
Support and Resistance
S3
S2
S1
Pivot
R1
R2
R3
S1
253.28
S2
247.42
S3
236.83
Pivot
263.87
R1
269.73
R2
280.32
R3
286.18
Moving Average
20 SMA
278.73
50 SMA
303.89
100 SMA
292.80
200 SMA
234.99
Marksans Pharma Ltd Corporate Actions
Marksans Pharma Ltd
₹0.6/Share
Announcement Date
17 Sep 2024
Record Date
17 Sep 2024
Div Yield
60%
Marksans Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in ₹ Cr) |
|---|---|---|
| Marksans Pharma Ltd | ₹259.20 | ₹11,746 |
| Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
| Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
| Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
| Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
| Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
Marksans Pharma Ltd News
Marksans Pharma to table results
On 11 February 2025
22 Jan 2025, 02:06 pm
Marksans Pharma gains after receiving final nod for Loratadine Tablets from USFDA
Marksans Pharma rose 1.94% to Rs 315 after the company received final approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) , Loratadine Tablets.
22 Nov 2024, 01:23 pm
Marksans Pharma receives USFDA approval for Loratadine Tablets
22 Nov 2024, 12:47 pm
Marksans Pharma gains after Q2 PAT rises 16% YoY to Rs 97 cr
Marksans Pharma added 2.70% to Rs 296.80 after the company reported 15.8% increase in consolidated net profit to Rs 96.72 crore on 20.83% rise in revenue from operations to Rs 641.92 crore in Q2 FY25 over Q2 FY24.
12 Nov 2024, 01:22 pm
Marksans Pharma to declare Quarterly Result
On 12 November 2024
23 Oct 2024, 05:41 pm
Marksans Pharma Ltd Stock Analysis
- Annual revenue for Marksans Pharma Ltd increased by 27.90% to ₹915.35 crore in FY 2024 from ₹715.69 crore in FY 2023.
- Annual Net Profit for Marksans Pharma Ltd increased by 30.03% to ₹133.76 crore in FY 2024 from ₹102.87 crore in FY 2023.
- Promoter Shareholding in Marksans Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 43.87% in September 2024 to 43.87% in December 2024.
- Marksans Pharma Ltd delivered a 1-year return of 72.59% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
- Marksans Pharma Ltd share price moved down by 2.59% from its previous close of INR ₹259.15. The latest Marksans Pharma Ltd share price is INR ₹252.45.
- Marksans Pharma Ltd share price today has been at a low of 246.05 and a high of 259.55. Over the past 52 weeks, the Marksans Pharma Ltd share price has seen a low of 130 and a high of 358.70.
About Marksans Pharma Ltd
Marksans Pharma Limited is a prominent Indian pharmaceutical company. It is primarily engaged in the manufacturing and marketing of pharmaceutical formulations. The company produces many finished dosage forms, including tablets, capsules, ointments, and liquids. Marksans Pharma is recognized for its dedication to quality and innovation. The company ensures that all its products comply with international standards.
Marksans Pharma operates in the pharmaceutical sector. Its primary focus is on the healthcare and life sciences industry. The company has been in business since 2000, giving it over two decades of experience in the pharmaceutical field. Its extensive experience has helped the company build a strong presence in domestic markets. Additionally, it has expanded its reach to international markets as well.
The headquarters of Marksans Pharma is located in Mumbai, Maharashtra. This strategic location enhances the company’s operations by providing logistical advantages. It also facilitates easy access to both national and global markets. Mr. Mark Saldanha promotes the company with 43.80% stakes. He plays a crucial role in its strategic direction and growth. A team of professional promoters manages the operations of the company-
Its primary products consist of various pharmaceutical formulations, including analgesics, antibiotics, and antidiabetics. Additionally, they produce cardiovascular drugs and gastrointestinal medications. The company also produces over-the-counter (OTC) products and nutraceuticals. These products address multiple therapeutic areas, providing a broad spectrum of healthcare solutions. This approach ensures comprehensive treatment options for various medical conditions.
Marksans Pharma plays a significant role in the pharmaceutical sector. However, it is not the largest company in terms of market share or market capitalization. Yet, the company has carved out a niche by focusing on quality and innovation. The promoter shareholding in Marksans Pharma is significant, with Mr Mark Saldanha holding a notable stake. This ensures strong governance and strategic oversight for the company.
The registered office and registrar’s office of Marksans Pharma is in Mumbai, Maharashtra. Marksans Pharma Limited is a well-established pharmaceutical company. It is recognized for its diverse product range and unwavering commitment to quality. With strong promoter backing, Marksans Pharma continues to be a key player in the healthcare industry. Its strategic focus on innovation further strengthens its position in the market.
Marksans Pharma’s commitment to quality is one of its most notable impacts. The company ensures that all its products meet stringent international standards. This dedication to quality has earned it certifications from various global regulatory bodies. These include the US FDA, UK MHRA, and Australian TGA.
Innovation is another area where Marksans Pharma has made a significant impact. The company invests heavily in research and development to create improved pharmaceutical formulations. This focus on innovation has led to the development of advanced drug delivery systems and solutions.
The company’s impact extends to its role in making medications more accessible. Marksans Pharma produces a wide range of generic drugs, which are more affordable than their branded counterparts. This affordability makes essential medications accessible to a larger population, particularly in developing countries with limited healthcare resources. Marksans Pharma’s efforts in this area contribute to improving public health and reducing the burden of disease.
The economic impact of Marksans Pharma is also significant. The company employs thousands of people, contributing to economic growth and development. Marksans Pharma’s operations generate revenue for the government through taxes and duties, supporting public finances. The company’s investments in infrastructure and technology drive economic activity. These investments also create new opportunities for local businesses.
Marksans Pharma’s impact is also evident in its corporate social responsibility (CSR) initiatives. The company undertakes various projects aimed at improving the quality of life in the communities where it operates. These projects focus on areas such as education and rural development.
The company’s strong leadership and governance structure further enhance its impact. Marksans Pharma is promoted by Mr. Mark Saldanha, who provides strategic direction and oversight. The company's management team consists of experienced professionals. They are responsible for driving its growth and fostering innovation. This leadership ensures that Marksans Pharma remains focused on its goals and continues to deliver value to its stakeholders.
Marksans Pharma’s impact is also reflected in its ability to adapt to changing market dynamics. The company regularly reviews and updates its strategies. This ensures it stays competitive and can meet the evolving needs of its customers. This proactive approach allows Marksans Pharma to navigate challenges effectively. It also positions the company to seize opportunities in the ever-evolving pharmaceutical industry.
Marksans Pharma Limited has made a significant impact on the pharmaceutical industry through its commitment to quality and accessibility. With a focus on continuous improvement, Marksans Pharma is well-positioned for future growth. The company aims to maintain its positive impact in the pharmaceutical industry.
Marksans Pharma operates in the pharmaceutical sector. Its primary focus is on the healthcare and life sciences industry. The company has been in business since 2000, giving it over two decades of experience in the pharmaceutical field. Its extensive experience has helped the company build a strong presence in domestic markets. Additionally, it has expanded its reach to international markets as well.
The headquarters of Marksans Pharma is located in Mumbai, Maharashtra. This strategic location enhances the company’s operations by providing logistical advantages. It also facilitates easy access to both national and global markets. Mr. Mark Saldanha promotes the company with 43.80% stakes. He plays a crucial role in its strategic direction and growth. A team of professional promoters manages the operations of the company-
- Mark Saldanha
- Sandra Saldanha
- Varddhman V Jain
- Sunny Sharma
- Seetharama R Buddharaju
Its primary products consist of various pharmaceutical formulations, including analgesics, antibiotics, and antidiabetics. Additionally, they produce cardiovascular drugs and gastrointestinal medications. The company also produces over-the-counter (OTC) products and nutraceuticals. These products address multiple therapeutic areas, providing a broad spectrum of healthcare solutions. This approach ensures comprehensive treatment options for various medical conditions.
Marksans Pharma plays a significant role in the pharmaceutical sector. However, it is not the largest company in terms of market share or market capitalization. Yet, the company has carved out a niche by focusing on quality and innovation. The promoter shareholding in Marksans Pharma is significant, with Mr Mark Saldanha holding a notable stake. This ensures strong governance and strategic oversight for the company.
The registered office and registrar’s office of Marksans Pharma is in Mumbai, Maharashtra. Marksans Pharma Limited is a well-established pharmaceutical company. It is recognized for its diverse product range and unwavering commitment to quality. With strong promoter backing, Marksans Pharma continues to be a key player in the healthcare industry. Its strategic focus on innovation further strengthens its position in the market.
Impact of Marksans Pharma
Marksans Pharma Limited has made a significant impact on the pharmaceutical industry, both in India and globally. The company’s focus on quality and accessibility has enabled it to provide essential medications to millions of people. This impact is evident in various aspects of its operations and contributions to healthcare.Marksans Pharma’s commitment to quality is one of its most notable impacts. The company ensures that all its products meet stringent international standards. This dedication to quality has earned it certifications from various global regulatory bodies. These include the US FDA, UK MHRA, and Australian TGA.
Innovation is another area where Marksans Pharma has made a significant impact. The company invests heavily in research and development to create improved pharmaceutical formulations. This focus on innovation has led to the development of advanced drug delivery systems and solutions.
The company’s impact extends to its role in making medications more accessible. Marksans Pharma produces a wide range of generic drugs, which are more affordable than their branded counterparts. This affordability makes essential medications accessible to a larger population, particularly in developing countries with limited healthcare resources. Marksans Pharma’s efforts in this area contribute to improving public health and reducing the burden of disease.
The economic impact of Marksans Pharma is also significant. The company employs thousands of people, contributing to economic growth and development. Marksans Pharma’s operations generate revenue for the government through taxes and duties, supporting public finances. The company’s investments in infrastructure and technology drive economic activity. These investments also create new opportunities for local businesses.
Marksans Pharma’s impact is also evident in its corporate social responsibility (CSR) initiatives. The company undertakes various projects aimed at improving the quality of life in the communities where it operates. These projects focus on areas such as education and rural development.
The company’s strong leadership and governance structure further enhance its impact. Marksans Pharma is promoted by Mr. Mark Saldanha, who provides strategic direction and oversight. The company's management team consists of experienced professionals. They are responsible for driving its growth and fostering innovation. This leadership ensures that Marksans Pharma remains focused on its goals and continues to deliver value to its stakeholders.
Marksans Pharma’s impact is also reflected in its ability to adapt to changing market dynamics. The company regularly reviews and updates its strategies. This ensures it stays competitive and can meet the evolving needs of its customers. This proactive approach allows Marksans Pharma to navigate challenges effectively. It also positions the company to seize opportunities in the ever-evolving pharmaceutical industry.
Marksans Pharma Limited has made a significant impact on the pharmaceutical industry through its commitment to quality and accessibility. With a focus on continuous improvement, Marksans Pharma is well-positioned for future growth. The company aims to maintain its positive impact in the pharmaceutical industry.
View More
FAQ’s
What is the share price of Marksans Pharma Ltd today?
Marksans Pharma Ltd share price as on 22 Jan 2025 is ₹
252.45
What is the Market Cap of Marksans Pharma Ltd?
The market cap of Marksans Pharma Ltd stock is ₹11,743.74 Cr.
What is the PE Ratio of Marksans Pharma Ltd?
The Price to Earnings (P/E) Ratio of Marksans Pharma Ltd is 51.37
What is the PB Ratio of Marksans Pharma Ltd?
The Price to Book (P/B) Ratio of Marksans Pharma Ltd is 5.62
What is the 52 week high of Marksans Pharma Ltd Share Price?
The 52 week high of Marksans Pharma Ltd share price stands at ₹358.70
What is the 52 week low of Marksans Pharma Ltd Share Price?
The 52 week low of Marksans Pharma Ltd share price stands at ₹130
Open Free
Demat Account!
Enjoy ₹11 Brokerage on Stocks Delivery
Equity, F&O and
DP Charges
